Bailard, Inc. Alkermes Plc. Transaction History

Bailard, Inc.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Jul 20, 2023	BUY	$28.34 - $33.63 $195,177 - $231,609	6,887 New	6,887 $215,000
Q4 2022 Feb 02, 2023	BUY	$21.94 - $26.24 $177,428 - $212,202	8,087 New	8,087 $211,000
Q2 2022 Jul 27, 2022	SELL	$26.4 - $30.54 $84,480 - $97,728	-3,200 Reduced 30.51%	7,287 $217,000
Q1 2022 Apr 25, 2022	BUY	$23.07 - $27.99 $13,842 - $16,794	600 Added 6.07%	10,487 $276,000
Q4 2021 Feb 10, 2022	BUY	$21.47 - $32.08 $212,273 - $317,174	9,887 New	9,887 $230,000
Q3 2020 Nov 10, 2020	SELL	$16.16 - $20.66 $289,668 - $370,330	-17,925 Closed	0 $0
Q2 2020 Aug 12, 2020	BUY	$13.31 - $19.41 $238,581 - $347,924	17,925 New	17,925 $348,000
Q4 2018 Feb 05, 2019	SELL	$27.94 - $44.61 $167,640 - $267,660	-6,000 Closed	0 $0
Q2 2018 Aug 08, 2018	BUY	$40.56 - $51.36 $40,560 - $51,360	1,000 Added 20.0%	6,000 $247,000
Q4 2017 Feb 08, 2018	BUY	$47.69 - $55.39 $95,380 - $110,780	2,000 Added 66.67%	5,000 $0
Q4 2015 Jan 29, 2018	BUY	N/A	3,000	3,000 $0

372

175M

140K

143K

Ticker ALKS
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 164,254,000
Market Cap $5.9B
Description
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...

Get notified when there are updates to the investment portfolio of Bailard, Inc., based on Form 13F filings with the SEC.

Stay updated on Bailard, Inc. with notifications on news.